| Prev Close | 53.73 |
| Open | 52.47 |
| Day Low/High | 49.79 / 54.81 |
| 52 Wk Low/High | 33.36 / 55.70 |
| Volume | 31.55M |
Pfizer Inc. (PFE)
54.37
0.64
1.20
NYSE
| Exchange | NYSE |
| Shares Outstanding | 5612.87B |
| Market Cap | 294.11B |
| P/E Ratio | 23.58 |
| Div & Yield | N.A. (N.A) |
Should Investors Believe in Bounces as Markets Get Choppy?
Sector selection will remain paramount as pandemic effects continue to permeate.
Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
Why I Am Now Less Bearish
* While I am not bullish, I am less bearish * On a (tactical) trading and even on an investing basis, markets may have overreacted to the Omicron news on Friday * I covered a bunch of shorts on Friday * It might be time to consider being a bit more ...
Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
With the Virus Still in Charge, Pfizer Can Be Flexible: Here's My Plan
PFE has created what appears to potentially be the most effective antiviral for those already infected.
Variant's Grand Slam, Good Data, Going With the ETF Flow, Eye on Black Friday
Plus, a thought on how the Fed could approach tapering going forward.
5 Reasons to Bet on Biotech
Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.
Fingers Crossed for a Small-Cap Revenge Rally in 2022
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
McCarthy Stalls, Europe's COVID Surge, Mad Love for Ford, Apple's Car Play
Plus, the headline numbers don't come close to telling the story of Thursday's action in the equity markets, which had a case of bad breadth.
Johnson & Johnson Joins the Breakup Club: Here's How to Play It
J&J will be separating into two distinct firms, but not right away.
Traders Should Be Stopped Out of Biohaven Pharmaceutical
For now I would take a wait and see approach.
The Streaks End, Peloton Gadget, Rivian IPO, Utility Software, PayPal, Palantir
It was almost nice to be reminded that the saloon doors to the financial markets still swing both ways.
Putting Together an End-of-Year Trading Strategy
Let's review areas that are hot, those that are not, and how to position though January.
Overbought but So What, The Beats Go On, Elon Musk's Tesla Share Sale Poll
Tesla's CEO steals some of rival Rivian's IPO thunder by asking the Twitter universe to decide if he should sell 10% of his Tesla shares.
Options Play of the Week: Dipping Into Dynavax
Knee-jerk reactions to earnings results can create attractive opportunities.
Traders Get Uplifting News, but Still Need a Rest
The jobs report and COVID numbers bring smiles to investors, but the key will be navigating the rotations as stocks become extended.
The Long and Short of It
I expect Boeing to get a bump off the news from Pfizer of a successful COVID-19 antiviral pill. I've been adding almost daily to Boeing. Also, I'm adding to Citigroup in premarket trading. And I have added to my small Tesla short.
Nasdaq Runs Higher, Semis Run Hot, EV Market Heats Up, Peloton Cools Down
Plus, we continue to wait with bated breath to see where Congress goes with President Biden's two big spending initiatives.
FibroGen Feedback
I continue to get good feedback with regard to FibroGen. The above is part of a publication on myelodysplastic syndrome. I would note that Acceleron is being acquired by Merck for $11 billion. Acceleron has a drug on market which treats 15%-20% ...
Pfizer Is a Low-Beat, Dividend Stock: Here's What Patient Investors Can Do
Pfizer attributed the quarter's sales of Comirnaty, the firm's Covid-19 Messenger RNA vaccine, for the size of the top and bottom line beats.
Money Is Moving, Midcap Opportunity? Fed Meeting, Coal, Earnings Chatter, Rivian
How far behind the large-cap indexes the S&P 400 and S&P 600 really are is astounding.
Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals
The lack of urgency at the FDA, as it is in the defense space, is alarming.
These Microcaps Are Making Some Big Noise
I attended the LD Micro Conference in Los Angeles. Here's what I found out.
Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer
With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.
Don't Own Merck Stock Yet? Here's My Prescription
I am in this one for the medium to long term.
Bonds Finally React, TINA Sticks Around, Booster Confusion, Salesforce Love
Plus, a look at where central bank policies appear to be heading.
Fed Speaks, Taper Timeline, Dot Fantasy, Evergrande, DC Circus, Booster Stocks
It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.
